EA201390612A1 - Биоразлагаемая композиция для доставки лекарственного средства - Google Patents
Биоразлагаемая композиция для доставки лекарственного средстваInfo
- Publication number
- EA201390612A1 EA201390612A1 EA201390612A EA201390612A EA201390612A1 EA 201390612 A1 EA201390612 A1 EA 201390612A1 EA 201390612 A EA201390612 A EA 201390612A EA 201390612 A EA201390612 A EA 201390612A EA 201390612 A1 EA201390612 A1 EA 201390612A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- drug delivery
- composition
- delivery
- medicines
- biodegradable composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title 1
- 238000012377 drug delivery Methods 0.000 abstract 3
- 230000009286 beneficial effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000839 emulsion Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
В изобретении предлагается биоразлагаемая композиция для доставки лекарственного средства, которая включает носитель и нерастворимый компонент, содержащий полезный агент, диспергированный в носителе. Как правило, композиция не является эмульсией, но обладает малой вязкостью и дополнительно обеспечивает минимальный первоначальный выброс, а также длительное высвобождение полезного агента во времени. Помимо этого предлагаются наборы, включающие биоразлагаемую композицию для доставки лекарственного средства или ее компоненты, а также способы изготовления и использования подобной биоразлагаемой композиции для доставки лекарственного средства.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41712610P | 2010-11-24 | 2010-11-24 | |
US201161563469P | 2011-11-23 | 2011-11-23 | |
PCT/US2011/062139 WO2012074883A1 (en) | 2010-11-24 | 2011-11-23 | Biodegradable drug delivery composition |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201390612A1 true EA201390612A1 (ru) | 2014-08-29 |
EA026964B1 EA026964B1 (ru) | 2017-06-30 |
Family
ID=46172227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201390612A EA026964B1 (ru) | 2010-11-24 | 2011-11-23 | Биоразлагаемая композиция для доставки лекарственного средства (варианты) |
Country Status (13)
Country | Link |
---|---|
US (5) | US20120225033A1 (ru) |
EP (1) | EP2643009A4 (ru) |
JP (4) | JP2013543898A (ru) |
KR (1) | KR20140015266A (ru) |
CN (2) | CN103384528B (ru) |
AU (3) | AU2011336896B2 (ru) |
BR (1) | BR112013011967A2 (ru) |
CA (1) | CA2812102A1 (ru) |
EA (1) | EA026964B1 (ru) |
MX (1) | MX347014B (ru) |
TW (1) | TWI538687B (ru) |
WO (1) | WO2012074883A1 (ru) |
ZA (1) | ZA201302120B (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
ES2562878T3 (es) | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
JP5510908B2 (ja) * | 2010-02-26 | 2014-06-04 | 株式会社ピーアイ技術研究所 | 半導体装置用ポリイミド樹脂組成物並びにそれを用いた半導体装置中の膜形成方法及び半導体装置 |
ES2390439B1 (es) | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | Composición inyectable |
US20140294977A1 (en) * | 2011-11-23 | 2014-10-02 | Durect Corporation | Radiation-Sterilized Biodegradable Drug Delivery Composition |
CA2903769A1 (en) | 2013-03-11 | 2014-10-09 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
KR101513812B1 (ko) * | 2013-11-22 | 2015-04-20 | 가천대학교 산학협력단 | 소수성 약물 전달용 마이크로 구조체의 제조방법 |
CA2931547A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
JP7051721B2 (ja) * | 2016-06-30 | 2022-04-11 | デュレクト コーポレーション | デポー製剤 |
US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
EA201990127A1 (ru) * | 2016-12-30 | 2020-08-18 | Дьюрект Корпорейшн | Депо-препарат |
PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
WO2022093722A1 (en) * | 2020-10-27 | 2022-05-05 | Pts Consulting, Llc | A liquid injectable composition of donepezil |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4853218A (en) * | 1987-02-24 | 1989-08-01 | Schering Corporation | Zinc-protamine-alpha interferon complex |
JPH07116160B2 (ja) * | 1987-08-10 | 1995-12-13 | 浜理薬品工業株式会社 | 結晶性l−カルノシン亜鉛錯体およびその製造法 |
IT1244647B (it) * | 1991-02-05 | 1994-08-08 | Salvatore Mancuso | Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo. |
US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5968542A (en) * | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
CA2372994C (en) * | 1999-06-04 | 2010-03-23 | Alza Corporation | Implantable gel compositions and method of manufacture |
ES2253375T3 (es) * | 2000-04-19 | 2006-06-01 | Genentech, Inc. | Formulaciones de liberacion sostenida. |
CA2439120C (en) * | 2001-02-23 | 2011-07-05 | Genentech, Inc. | Erodible polymers for injection |
WO2003058203A2 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
NZ571243A (en) * | 2002-12-31 | 2010-04-30 | Altus Pharmaceuticals Inc | Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine |
SI1605897T1 (sl) | 2003-03-19 | 2012-11-30 | Lilly Co Eli | Polietilen glikol povezane GLP spojine |
CA2530136C (en) * | 2003-06-26 | 2012-10-16 | Control Delivery Systems, Inc. | In-situ gelling drug delivery system |
EP1670486A4 (en) * | 2003-10-01 | 2009-04-01 | Optimer Pharmaceuticals Inc | TREATMENT OF A CONDITION IN A MAMMALIAN WITH ADMINISTRATION OF AMINO SUGAR AND USES THEREOF |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
PL1809329T3 (pl) * | 2004-09-17 | 2012-08-31 | Durect Corp | Kompozycja znieczulająca zawierająca saib o przedłużonym uwalnianiu do stosowania miejscowego |
AU2005304435B8 (en) * | 2004-11-10 | 2011-06-23 | Tolmar Therapeutics, Inc. | A stabilized polymeric delivery system |
CN101060856B (zh) * | 2004-11-22 | 2011-01-19 | 诺和诺德公司 | 可溶、稳定的含胰岛素制剂 |
US20060142234A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
EP2364735A3 (en) | 2005-12-16 | 2012-04-11 | Nektar Therapeutics | Branched PEG conjugates of GLP-1 |
US20100022457A1 (en) * | 2006-05-26 | 2010-01-28 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
EP2139526A4 (en) * | 2007-04-03 | 2010-07-14 | Trimeris Inc | NEW FORMULATIONS TO RELEASE ANTIVIRAL PEPTIDE THERAPEUTICS |
JP5599705B2 (ja) * | 2007-05-18 | 2014-10-01 | デュレクト コーポレーション | 改良されたデポー製剤 |
ES2562878T3 (es) * | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
-
2011
- 2011-11-23 US US13/304,174 patent/US20120225033A1/en not_active Abandoned
- 2011-11-23 CA CA2812102A patent/CA2812102A1/en not_active Abandoned
- 2011-11-23 AU AU2011336896A patent/AU2011336896B2/en not_active Ceased
- 2011-11-23 MX MX2013005621A patent/MX347014B/es active IP Right Grant
- 2011-11-23 BR BR112013011967A patent/BR112013011967A2/pt not_active Application Discontinuation
- 2011-11-23 WO PCT/US2011/062139 patent/WO2012074883A1/en active Application Filing
- 2011-11-23 TW TW100142917A patent/TWI538687B/zh not_active IP Right Cessation
- 2011-11-23 KR KR1020137010522A patent/KR20140015266A/ko not_active Application Discontinuation
- 2011-11-23 EP EP11846033.6A patent/EP2643009A4/en active Pending
- 2011-11-23 CN CN201180051945.0A patent/CN103384528B/zh active Active
- 2011-11-23 EA EA201390612A patent/EA026964B1/ru not_active IP Right Cessation
- 2011-11-23 CN CN201610159859.6A patent/CN105748402B/zh active Active
- 2011-11-23 JP JP2013541064A patent/JP2013543898A/ja not_active Revoked
-
2013
- 2013-03-07 US US13/789,580 patent/US20130259907A1/en not_active Abandoned
- 2013-03-20 ZA ZA2013/02120A patent/ZA201302120B/en unknown
- 2013-12-10 US US14/102,453 patent/US20140193365A1/en not_active Abandoned
-
2016
- 2016-03-23 AU AU2016201819A patent/AU2016201819B2/en not_active Ceased
- 2016-11-18 US US15/356,488 patent/US20170189547A1/en not_active Abandoned
-
2017
- 2017-02-06 JP JP2017019820A patent/JP2017114877A/ja active Pending
-
2018
- 2018-03-02 AU AU2018201533A patent/AU2018201533A1/en not_active Abandoned
- 2018-07-12 JP JP2018132025A patent/JP6837457B2/ja active Active
- 2018-11-02 US US16/179,704 patent/US20190209654A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021017896A patent/JP2021073295A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6837457B2 (ja) | 2021-03-03 |
AU2011336896A1 (en) | 2013-04-11 |
EP2643009A1 (en) | 2013-10-02 |
WO2012074883A1 (en) | 2012-06-07 |
JP2013543898A (ja) | 2013-12-09 |
AU2011336896B2 (en) | 2015-12-24 |
AU2016201819A1 (en) | 2016-04-14 |
US20140193365A1 (en) | 2014-07-10 |
CN103384528A (zh) | 2013-11-06 |
JP2018188457A (ja) | 2018-11-29 |
US20190209654A1 (en) | 2019-07-11 |
US20130259907A1 (en) | 2013-10-03 |
US20170189547A1 (en) | 2017-07-06 |
TWI538687B (zh) | 2016-06-21 |
AU2016201819B2 (en) | 2017-12-14 |
CN105748402B (zh) | 2022-06-03 |
MX347014B (es) | 2017-04-07 |
ZA201302120B (en) | 2014-05-28 |
BR112013011967A2 (pt) | 2016-08-30 |
JP2021073295A (ja) | 2021-05-13 |
AU2018201533A1 (en) | 2018-03-22 |
CA2812102A1 (en) | 2012-06-07 |
MX2013005621A (es) | 2013-12-06 |
KR20140015266A (ko) | 2014-02-06 |
EP2643009A4 (en) | 2015-04-01 |
US20120225033A1 (en) | 2012-09-06 |
CN103384528B (zh) | 2016-04-13 |
TW201306869A (zh) | 2013-02-16 |
CN105748402A (zh) | 2016-07-13 |
EA026964B1 (ru) | 2017-06-30 |
JP2017114877A (ja) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201390612A1 (ru) | Биоразлагаемая композиция для доставки лекарственного средства | |
CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
BR112018010720A2 (pt) | agonistas do receptor de apelina e métodos de uso | |
EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
CL2012003293A1 (es) | Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson. | |
CL2009000178A1 (es) | Composicion que comprende un anticuerpo contra el dominio ii de her2, sus variantes acidas, secuencias que comprenden las cadenas livianas y pesadas de este; formulacion farmaceutica que comprende dicho anticuerpo y uso de este para cancer her2 positivo. | |
EA201690492A1 (ru) | Проникающие в клетку конъюгаты и способы их применения | |
EA201591961A1 (ru) | Ингибиторы акк и их применение | |
EA201591959A1 (ru) | Ингибиторы акк и их применение | |
EA201591960A1 (ru) | Ингибиторы акк и их применение | |
EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
EA201591196A1 (ru) | Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств | |
EA201390821A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты и их применение | |
EA201490826A1 (ru) | Ингибиторы асс и их применения | |
EA201001680A1 (ru) | Соединения бензолсульфонамидтиазола и оксазола | |
BR122020024446B8 (pt) | Compostos para modulação da expressão do receptor do hormônio de crescimento | |
EA201591962A1 (ru) | Ингибиторы акк и их применение | |
EA201490688A1 (ru) | 2-тиопиримидиноны | |
EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
CY1120488T1 (el) | Υγρη φαρμακευτικη συνθεση | |
BR112012028037A2 (pt) | formulação de pró-emulsão líquida de taxano não aquosa, métodos para administrar um taxano a um paciente e para fabricar uma formulação de pró-emulsão de taxano, composição de emulsão de taxano, e, kit | |
BR112015032277A2 (pt) | composições e métodos para imunoterapia | |
EA202090508A1 (ru) | Изготовление фармацевтических составов | |
BR112014032764A2 (pt) | composição farmacêutica contendo fimasartana e hidroclorotiazida | |
EA201690005A1 (ru) | Состав с модифицированной кинетикой высвобождения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |